Hjem › Ikke-småcellet lungecancer › Texas › Austin
Ikke-småcellet lungecancer kliniske forsøg i Austin, TX
30 studier for Ikke-småcellet lungecancer søger deltagere på steder i og omkring Austin (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruttererFase 1/2
- New Experimental Therapeutics - NEXT Oncology, Austin
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RekruttererFase 1
- NEXT Austin, Austin
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekruttererFase 1
- Exelixis Clinical Site #46, Austin
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
RekruttererFase 3
- Texas Oncology-Austin Central, Austin
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RekruttererFase 3
- Texas Oncology - South Austin, Austin
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RekruttererFase 3
- Texas Oncology- Central South., Austin
- Texas Oncology Central South, Austin
- Texas Oncology- Central South., Austin
- og 1 flere
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RekruttererFase 3
- Texas Oncology - Central/South Texas, Austin
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RekruttererFase 2
- Texas Oncology South, Austin
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
RekruttererFase 1/2
- Next Oncology - Austin, Austin
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RekruttererFase 3
- Clinical Study Site, Austin
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RekruttererFase 1/2
- Texas Oncology (Balcones) - SCRI, Austin
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RekruttererFase 2/3
- Local Institution - 007-892-B, Austin
- Local Institution - 007-892-A, Austin
- USOR - Texas Oncology - Dallas Fort Worth (DFW) - South Austin, Austin
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RekruttererFase 1
- NEXT Oncology - Austin, Austin
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RekruttererFase 3
- USO - Texas Oncology, Austin
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RekruttererFase 1
- NEXT Oncology Texas, Austin
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
RekruttererFase 3
- Research Site, Austin
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
RekruttererFase 1
- NEXT Oncology - Austin, Austin
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekruttererFase 1/2
- Texas Oncology - Central / South Texas, Austin
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RekruttererFase 1
- NEXT Oncology Austin /ID# 243005, Austin
Study of XB010 in Subjects With Solid Tumors
RekruttererFase 1
- NEXT Austin, Austin
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
RekruttererFase 1
- NEXT Texas LLC - Austin, Austin
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
RekruttererFase 1
- NEXT Texas LLC - Austin, Austin
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
RekruttererFase 2
- Texas Oncology - Austin Central, Austin
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
RekruttererFase 3
- Sarah Cannon Research Institute (SCRI) - Texas Oncology-Central South, Austin
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
RekruttererFase 1/2
- University of Texas at Austin, Austin
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
RekruttererFase 1
- NEXT Oncology, Austin, TX 78758
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
RekruttererFase 1
- Dren Investigational Site, Austin
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RekruttererFase 1/2
- Research Site 135, Austin
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
RekruttererFase 2
- TxO Central/South, Texas Oncology -Central/South Texas, Austin
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RekruttererFase 1/2
- NEXT Austin, Austin
Ikke-småcellet lungecancer forsøg i andre byer
- Houston, TX145 studier
- New York City, NY120 studier
- Arlington, VA104 studier
- Nashville, TN97 studier
- Boston, MA90 studier
- Los Angeles, CA87 studier
- St. Louis, MO73 studier
- Chicago, IL61 studier
- Baltimore, MD60 studier
- San Antonio, TX59 studier
- Columbus, OH56 studier
- Washington, DC55 studier
Andre studier i Austin
- Kræft (alle typer)20 studier
- Overvægt20 studier
- Metastatisk cancer19 studier
- Colorektal kræft19 studier
- Hjertesvigt18 studier
- Brystkræft18 studier
- Overvægt18 studier
- Ægstockræft17 studier
- Livmoderslimhindekræft15 studier
- Prostatakræft15 studier
- Depression14 studier
- Tripelnegativ brystkræft13 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.